
Mirata Pharmaceuticals: Innovating powerful, opioid-based pain relief solutions for patients and physicians.
Mirata Pharmaceuticals is dedicated to innovating powerful, opioid-based pain relief solutions for patients and physicians. The company focuses on developing the next generation of analgesic medications that harness the pain-relieving benefits of opioids while addressing their addictive properties and adverse side effects. Mirata aims to provide effective pain management options in a market heavily impacted by the opioid crisis, which poses significant medical, societal, and economic challenges.
Mirata Pharmaceuticals has made notable strides in the pharmaceutical industry by addressing the critical need for safer opioid alternatives. Their work contributes to reducing the societal and economic burdens associated with opioid addiction and misuse. Through their innovative approach, Mirata seeks to improve patient outcomes and offer viable pain management solutions, positioning themselves as a key player in the fight against the opioid epidemic.

Elite Pharmaceuticals
elitepharma.com

Maxona Pharmaceuticals
maxonapharm.com

Melt Pharmaceuticals

Mirum Pharmaceuticals
mirumpharma.com

Phoenix PharmaLabs

Tremeau Pharmaceuticals

Solace Pharmaceuticals

Quartet Medicine

Amalgent Therapeutics
amalgent.com
Mira Oncology

Trigemina

Sapir Pharmaceuticals

Aiko Biotechnology
Pacira BioSciences
pacira.com

Concentric Analgesics
Companies similar to Mirata Pharmaceuticals include Elite Pharmaceuticals, Maxona Pharmaceuticals, Melt Pharmaceuticals and Mirum Pharmaceuticals.
Mirata Pharmaceuticals was founded in 2017.
Mirata Pharmaceuticals' headquarters is located in Plymouth Meeting, PA, US.
Mirata Pharmaceuticals' most recent funding round was for $3.9M (USD) in July 2018.
As of Jul 4, 2018, Mirata Pharmaceuticals has raised a total of $11M (USD).
Mirata Pharmaceuticals has 5 employees as of Feb 5, 2024.